. 2017 Oct;23(10):10.18553/jmcp.2017.23.10.1010. doi: 10.18553/jmcp.2017.23.10.1010

TABLE 2.

Model Results Under an Expected Value Indication-Based Price and an Outcomes Guarantee

Indication	Treatment Arm	Total Cost Per Mean Duration of Postprogression Survival ($)	Total Cost Per Mean Duration of PFS + Postprogression Survival ($)	Preprogression QALY	Postprogression QALY	Incremental Preprogression QALY	Incremental Postprogression QALY	Total Incremental QALY	ICER ($ per QALY)	ICER Target ($ per QALY)	Adjusted Unit Price ($ per mg)	Monthly Price ($ per 4 Weeks Continuation of Therapy)
Results under an expected value indication-based price
Metastatic breast cancer	Trastuzumab + chemotherapy^a	29,986.56	95,715.06	0.7	1.0	0.2	0.1	0.4	260,857	150,000	3.50	2,270.80
Metastatic breast cancer	Chemotherapy alone^a	29,986.56	95,715.06	0.5	0.9	0.2	0.1	0.4	260,857	150,000	3.50	2,270.80
Advanced gastric cancer	Trastuzumab + chemotherapy^b	33,066.57	81,456.10	0.7	0.5	0.1	0.1	0.3	321,746	150,000	0.93	691.30
Advanced gastric cancer	Chemotherapy alone^b	33,066.57	81,456.10	0.5	0.4	0.1	0.1	0.3	321,746	150,000	0.93	691.30
Results under an outcomes guarantee
Metastatic breast cancer	Trastuzumab + chemotherapy^a	40,193.54	135,128.84	1.0	1.6	0.7	0.2	0.9	156,159	150,000	8.66	5,623.40
Metastatic breast cancer	Chemotherapy alone^a	40,193.54	135,128.84	0.3	1.4	0.7	0.2	0.9	156,159	150,000	8.66	5,623.40
Advanced gastric cancer	Trastuzumab + chemotherapy^b	46,293.20	99,450.62	0.7	0.5	0.2	0.2	0.3	314,419	150,000	0.20	147.60
Advanced gastric cancer	Chemotherapy alone^b	46,293.20	99,450.62	0.6	0.4	0.2	0.2	0.3	314,419	150,000	0.20	147.60

^aChemotherapy may be an anthracycline with cyclophosphamide or paclitaxel alone.¹⁶

^bChemotherapy is a fluoropyrimidine and cisplatin.¹⁵

ICER = incremental cost-effectiveness ratio; PFS = progression-free survival; QALY = quality-adjusted life-year.